Last 15 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -105.25 | — | 18.72 | — | — | — | — | 12.86 | — | 22.02 | — | 0.47 | — | — | — | — |
| — | — | — | — | — | — | — | +2661.8% | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3729.04 | 4422.38 | 2232.18 | 1891.18 | 1639.52 | 883.28 | 235.69 | 237.02 | 474.15 | 258.50 | 73.13 | 152.35 | 616.52 | 88.48 | 50.04 | 83.56 |
| — | +400.7% | +847.1% | +697.9% | +245.8% | +241.7% | +222.3% | +55.6% | -23.1% | +192.1% | +46.1% | +82.3% | — | — | — | — | |
| P/B Ratio | 5.10 | 5.18 | 4.25 | 3.04 | 2.14 | 1.59 | 1.38 | 1.54 | 1.52 | 1.40 | 1.31 | 1.44 | 6.79 | 5.74 | 3.41 | 3.99 |
| — | +225.5% | +209.0% | +96.8% | +41.0% | +13.6% | +4.8% | +7.2% | -77.6% | -75.6% | -61.5% | -63.9% | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 0.16 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 11.66 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 84.4% | 80.3% | 87.3% | 65.0% | 92.9% | 92.9% | 97.3% | 97.1% | 94.8% | 97.3% | 84.7% | 98.7% | 93.9% | 80.5% | 65.7% | 51.2% |
| — | -13.6% | -10.3% | -33.1% | -1.9% | -4.6% | +14.8% | -1.6% | +0.9% | +20.9% | +29.0% | +92.9% | — | — | — | — | |
| Operating Margin | -15560.6% | -25380.9% | -14087.1% | -16966.1% | -19492.9% | -13130.0% | -3764.4% | -3042.6% | -7636.0% | -1279.5% | -919.5% | 32948.6% | -5863.2% | -1278.3% | -855.4% | -1644.0% |
| — | -93.3% | -274.2% | -457.6% | -155.3% | -926.2% | -309.4% | -109.2% | -30.2% | -0.1% | -7.5% | +2104.2% | — | — | — | — | |
| Net Margin | -3629.2% | -13164.4% | 12023.6% | -13301.2% | -7225.9% | -10292.9% | -2727.5% | 1878.3% | -5143.8% | 1192.7% | -522.3% | 32747.6% | -8342.3% | -1349.5% | -122.8% | -2064.4% |
| — | -27.9% | +540.8% | -808.2% | -40.5% | -963.0% | -422.2% | -94.3% | +38.3% | +188.4% | -325.4% | +1686.3% | — | — | — | — |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -5.7% | -3.7% | 5.9% | -5.4% | -2.4% | -4.5% | -3.9% | 3.0% | -4.0% | 1.5% | -2.3% | 128.9% | -22.9% | -19.8% | -2.2% | -24.7% |
| — | +16.8% | +253.3% | -278.4% | +41.2% | -389.2% | -66.1% | -97.6% | +82.5% | +107.8% | -4.7% | +622.4% | — | — | — | — | |
| ROA | -5.4% | -3.4% | 5.5% | -5.2% | -2.2% | -4.3% | -3.7% | 2.8% | -3.6% | 1.4% | -2.1% | 108.7% | -14.5% | -12.9% | -1.5% | -16.0% |
| — | +19.4% | +250.4% | -283.1% | +37.9% | -407.1% | -76.9% | -97.4% | +75.0% | +110.8% | -42.0% | +780.1% | — | — | — | — | |
| ROIC | -29.4% | -7.1% | -6.9% | -6.9% | -6.3% | -6.8% | -6.9% | -5.6% | -12.0% | -15.3% | -47.9% | 926.4% | -40.2% | -51.8% | -44.6% | -56.0% |
| — | -3.5% | -0.9% | -22.8% | +48.0% | +55.3% | +85.6% | -100.6% | +70.1% | +70.5% | -7.5% | +1753.9% | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.04 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.06 | 0.08 | 0.08 | 0.38 | 0.37 | 0.30 | 0.34 |
| — | +5.2% | +5.1% | +130.1% | +117.8% | -67.8% | -75.1% | -76.4% | -97.5% | -82.6% | -74.4% | -77.1% | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 0.10 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 18.37 | 16.72 | 18.37 | 30.66 | 33.70 | 40.54 | 33.47 | 37.91 | 10.43 | 27.91 | 25.24 | 27.79 | 5.84 | 6.37 | 6.60 | 6.74 |
| — | -58.8% | -45.1% | -19.1% | +223.2% | +45.3% | +32.6% | +36.4% | +78.5% | +338.0% | +282.3% | +312.4% | — | — | — | — | |
| Quick Ratio | 18.37 | 16.72 | 18.37 | 30.66 | 33.70 | 40.54 | 33.47 | 37.91 | 10.43 | 27.75 | 25.10 | 27.77 | 5.82 | 6.35 | 6.59 | 6.74 |
| — | -58.8% | -45.1% | -19.1% | +223.2% | +46.1% | +33.3% | +36.5% | +79.0% | +336.7% | +280.9% | +312.1% | — | — | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | -15.87 | — | -23.40 | -21.62 | -35.59 | -19.90 | -44.24 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 15 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ROIV stock.
Roivant Sciences Ltd.'s current P/E is -105.3x. The average P/E over the last 1 quarters is 18.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Roivant Sciences Ltd.'s current operating margin is -15560.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Roivant Sciences Ltd.'s business trajectory between earnings reports.